Scalper1 News
Shareholders of generic-drug giant Mylan (MYL) on Friday voted in favor of continuing the firm’s hostile bid for Perrigo (PRGO), launching what could be a protracted battle. Mylan said two-thirds of shareholders had approved both the transaction and the issuance of shares to Perrigo shareholders for the cash-and-stock bid, which as of Mylan’s last formal proposal in April was worth $205 a share. Perrigo, the subject of today’s New America profile, Scalper1 News
Scalper1 News